KINNEAR PHARMACEUTICALS ANNOUNCES FUNDING AGREEMENT WITH THE CYSTIC FIBROSIS FOUNDATION – Business

iCrowdNewswire   Jan 26, 2021  9:00 AM ET
Support for preclinical testing for a novel broad spectrum inhaled anti-infective that rapidly eradicates microbial biofilms which are present in the lungs of Cystic Fibrosis patients
DUBLIN,OHIO (26 January 2021) Kinnear Pharmaceuticals (Kinnear)announces an agreement with the Cystic Fibrosis Foundation on a staged Therapeutic Development Award (TDA) providing development funds for Kinnear’s lead compound, CSA-131. The staged award of up to $3 million, supported with matching funds from Kinnear, provides funding for preclinical research to enable the filing of an Investigational New Drug (IND) application with the FDA in 2022.
“We are pleased and honored to announce this agreement with the Cystic Fibrosis Foundation to help progress CSA-131 as a novel therapeutic drug candidate for CF lung infections. Individuals living with CF are frequently burdened with life-threatening lung infections resulting from highly drug-resistant bacteria and fungi that produce biofilms, including

Related Keywords

Dublin ,Ireland ,Carl Genberg ,Kinnear Pharmaceuticals ,Cystic Fibrosis Foundation ,Therapeutic Development Award ,Cystic Fibrosis ,Investigational New Drug ,Chief Executive Officer ,Cerashield Endotracheal Tube ,Relations Contacts ,Respiratory Infections ,Inhaled Drug ,Financial Market ,டப்ளின் ,ஐயர்ல்யாஂட் ,கிநிர் மருந்துகள் ,சிஸ்டிக் ஃபைப்ரோஸிஸ் அடித்தளம் ,சிகிச்சை வளர்ச்சி விருது ,சிஸ்டிக் ஃபைப்ரோஸிஸ் ,தலைமை நிர்வாகி அதிகாரி ,உறவுகள் தொடர்புகள் ,சுவாச நோய்த்தொற்றுகள் ,நிதி சந்தை ,